Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose vs Standard-Dose Chemotherapy in Metastatic Breast Cancer
NCT00012311Phase 2Unknown
- Sponsor
- Herbert Irving Comprehensive Cancer Center
- Start
- Jan 2000
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ifosfamide, etoposide, carboplatin, thiotepa, cyclophosphamide and 3 more in breast cancer (2 arms), sponsored by Herbert Irving Comprehensive Cancer Center. Status: unknown.
02
Drugs
ifosfamideetoposidecarboplatinthiotepacyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00012311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012311.